Patents by Inventor Paul Kubes

Paul Kubes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108686
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Application
    Filed: June 5, 2023
    Publication date: April 4, 2024
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing SZE Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Patent number: 11666631
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: June 6, 2023
    Assignee: Arch Biopartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Publication number: 20220251140
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Application
    Filed: February 14, 2022
    Publication date: August 11, 2022
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
  • Patent number: 11286278
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: March 29, 2022
    Assignee: Arch BioPartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
  • Patent number: 11083773
    Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 10, 2021
    Assignee: ARCH CANCER THERAPEUTICS, INC.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
  • Publication number: 20200223888
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Application
    Filed: December 2, 2019
    Publication date: July 16, 2020
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
  • Publication number: 20200078442
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Application
    Filed: July 8, 2019
    Publication date: March 12, 2020
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing SZE Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Patent number: 10493127
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 3, 2019
    Assignee: Arch Biopartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Patent number: 9464114
    Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 11, 2016
    Assignee: ARCH CANCER THERAPEUTICS, INC.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
  • Patent number: 9422335
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 23, 2016
    Assignee: UTI Limited Partnership
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Publication number: 20150065414
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammtory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 5, 2015
    Applicant: UTI LIMITED PARTNERSHIP
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Publication number: 20140329766
    Abstract: The present disclosure pertains to antimicrobial compositions for intravenous administration to patients who have experienced a serious brain trauma, to reduce the risk of occurrence of post-trauma microbial infections. The antimicrobial compositions comprise an ?-galacytosylceramide compound and one or more excipients. The present disclosure also pertains to the use of ?-galacytosylceramide compounds for the manufacture of antimicrobial medicaments for intravenous administration to patients with serious brain traumas. The present disclosure also pertains to methods for the prophylactic use of the antimicrobial compositions to reduce the risks of occurrence of post-trauma microbial infections.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 6, 2014
    Inventors: Connie Hoi Yee Wong, Paul Kubes, Steven A. Porcelli